checkAd
    KalVista Pharmaceuticals Aktie
    12,080
     
    USD
    -0,08 %
    -0,010 USD
    Letzter Kurs 02:00:00 Nasdaq
    12,080
     
    USD
    600 STK
    Geldkurs 10.05.24
    12,100
     
    USD
    3.500 STK
    Briefkurs 10.05.24
    ISIN: US4834971032 · WKN: A2DG49 · SYM: KALV · USA

    Neueste Nachrichten

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    02.05.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
    01.05.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
    22.04.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
    03.04.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    02.04.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
    18.03.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
    12.03.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
    11.03.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
    08.03.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
    07.03.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
    06.03.24 · Business Wire (engl.) · KalVista Pharmaceuticals
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.03.24 · Business Wire (engl.) · KalVista Pharmaceuticals